Researchers have engineered a method to convert standard antibodies into compact intracellular molecules capable of targeting disease-causing proteins inside human cells. This advancement could enable treatments for neurodegenerative diseases including Alzheimer's, Parkinson's, Huntington's disease, and motor neurone disease.
Traditional antibodies operate outside cells, making them unable to reach pathogenic proteins trapped within the cell's interior. The new approach redesigns antibodies into smaller structures, called intrabodies, that penetrate cell membranes and neutralize toxic proteins from within. Artificial intelligence guided the design process, streamlining the engineering of these molecules for optimal effectiveness.
The research targets a fundamental problem in neurodegenerative disease treatment. Alzheimer's involves accumulation of amyloid-beta and tau proteins. Parkinson's involves alpha-synuclein aggregation. Motor neurone disease involves TDP-43 and SOD1 protein misfolding. These pathogenic proteins congregate inside neurons, beyond the reach of conventional antibody-based drugs currently used for other conditions.
By developing intrabodies that cross cell membranes, researchers create a new therapeutic window. AI optimization accelerates identification of designs with superior cell penetration and target binding. This reduces development timelines compared to traditional antibody engineering methods.
The work represents collaboration between computational biology and neuroscience, leveraging machine learning to solve a structural design problem that had resisted conventional approaches. The technology demonstrates how AI can accelerate protein engineering for previously intractable disease targets.
Challenges remain before clinical application. Researchers must confirm that intrabodies reach affected brain cells in living organisms, confirm they remain stable in the cellular environment, and establish safe delivery mechanisms across the blood-brain barrier. Manufacturing scalability and immunogenicity assessments also require investigation.
The findings provide a potential toolkit for developing treatments targeting intracell